Inato Pitch Deck Teardown: Scaling a Clinical Trial Marketplace for Community Sites

Inato’s Series A deck focuses on the inefficiency of the $50B clinical trial industry, where 70% of trials are concentrated in just 5% of sites. By positioning themselves as a marketplace rather than a site owner, Inato demonstrates a scalable model for unlocking access to patient populations that are currently underserved. The deck highlights significant traction, including partnerships with one-third of the top 30 global pharma sponsors and a network of over 2,000 community sites. While the deck is strong on vision and marketplace dynamics, it lacks a traditional team slide and specific fin…

Key takeaways

• The clinical trial industry is valued at $50B, but 40% of expenditures are lost to inefficient patient recruitment (Slide 2).
• Inato identifies a massive supply-demand mismatch where 70% of trials are funneled through only 5% of available sites (Slide 4).
• The company utilizes an 'asset-light' model, aiming to build the world's largest research network without owning any physical sites (Slide 5).
• Traction is evidenced by a network of 2,000+ community sites reached within two years (Slide 8).
• Inato has secured 10 of the top 30 global pharma sponsors, achieving 100% sponsor retention and 100% contract expansion within six months (Slide 9).
• The platform introduces the 'Inato Verified Commitment' (IVC) to guarantee enrollment performance to sponsors (Slide 7).
• Future growth targets a $15B total addressable market by expanding from matching ($3B TAM) into site services ($12B TAM) (Slide 11).
• The deck omits a dedicated team slide, detailed unit economics, and a specific funding ask (Slides 1-16).

Frequently asked questions

What is the core problem Inato is solving?

Inato addresses the 'broken' clinical trial industry where pharmaceutical sponsors compete for a tiny subset of patients. According to Slide 4, only 5% of healthcare sites currently run 70% of trials, leading to high costs and slow recruitment. Inato aims to bridge this gap by connecting sponsors to the other 95% of sites located in local communities.

How does Inato make money?

While the deck does not explicitly detail the fee structure, Slide 10 mentions the expansion into 'multimillion dollar annual contracts' with sponsors. The business model is a marketplace where sponsors pay for access to a verified network of community sites and recruitment services, moving from simple matching to comprehensive site services.

What is an 'Inato Verified Commitment' (IVC)?

As described on Slide 7, an IVC is the number of patients a site commits to enroll for a specific study, which is then verified by Inato. This acts as a performance guarantee for sponsors, reducing the risk of selecting unproven community sites and ensuring the trial stays on schedule.

Who are Inato's main customers?

Inato operates a two-sided marketplace. Their primary paying customers (Sponsors) are global pharmaceutical companies; Slide 9 notes they work with 10 of the top 30. Their supply side consists of 'Community Sites'—local clinics and hospitals that have the patient access but lack the infrastructure to attract major pharma trials.

What is missing from this pitch deck?

The deck is missing several standard Series A components: there is no team slide highlighting founder expertise, no slide detailing the specific use of funds or the amount being raised, and no detailed breakdown of unit economics or burn rate. It functions more as a strategic narrative than a full financial disclosure.

You’ve studied Inato’s deck. Now score yours.

Upload your pitch deck and get AI-powered feedback to strengthen your pitch.

• Overall score
• Slide-by-slide feedback
• Prioritized fixes

Get My Pitch Score

Inato pitch deck: the facts

Company

Inato

Year

2023

Stage

Series A

Slides

16

Sector

Healthcare

Outcome

$20M raised

Inato pitch deck PDF

The full Inato deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Inato pitch deck was used for

This deck is Inato’s 2023 Series A fundraise presentation, used to support a $20M+ round focused on expanding its clinical trial marketplace that connects global pharmaceutical sponsors with thousands of community-based research sites. The company’s platform aims to solve bottlenecks in clinical trial recruitment by unlocking patient access at underused community sites and making trials more inclusive. The raise was positioned to fund product innovation, international expansion, and hiring, particularly in the U.S. and other key markets.[1][9][10][14]

Business model: Inato operates a global clinical trial marketplace and AI-powered platform that matches community-based research sites with appropriate clinical trial protocols and connects sponsors, sites, and patients to make trials more inclusive and efficient.[4][5][11][12]

Round

Series A / Series A2[1][6][7][9][13]

Lead investor

Cathay Innovation[1][9][13][14]

Investors

Cathay Innovation, Obvious Ventures, La Maison, Top Harvest Capital[1][9][13][14]

Founded

2016[15]

Headquarters

Paris, France, with U.S. presence including Guilford, Connecticut.[11][15]

Industry

Healthcare / Clinical Trials Technology / Digital Health.[4][5][9]

Year: 2023[1][9][13][14]

Raised: $20M (Series A2, sometimes reported as approximately $21.3M)[1][6][7][9][13]

Total funding: Inato has raised at least $34M+: $14M Series A in 2020 plus a $20M Series A2 round announced in March 2023, with some databases reporting total funding around $37.5M across multiple rounds.[4][9][13][15]

Use of funds as presented: Continued product innovation of Inato’s clinical trial platform, international growth, and hiring of top talent to support more inclusive trials and broader site participation.[1][9][14]

What happened after the Inato deck

After raising a $14M Series A in 2020, Inato completed a roughly $20M Series A2 round in 2023 to scale its AI-powered clinical trial marketplace, focusing on inclusive recruitment and community-based sites; the company remains active and has gained industry recognition for its innovative approach to trial diversity.[1][4][9][10][14][15]

• Inato closed a $14M Series A round in 2020 led by Obvious Ventures and Cathay Innovation, with participation from Serena
• In March 2023, the company announced a $20M Series A2 funding round (often described as Series A) from Cathay Innovation
• Following the 2023 round, Inato emphasized continued product innovation, international expansion, and hiring, and was re

What the Inato deck got right

• Strong focus on solving a major clinical trial recruitment and diversity problem. Inato directly addresses a critical bottleneck in clinical research—patient recruitment—by focusing on community-based sites and underrepresented populations, creating a compelling impact and market-size story for healthcare investors.[4][5][9][10][15]
• Clear differentiation through an AI-enabled marketplace model. The company’s positioning as a global marketplace and AI-powered platform that matches sites and protocols offers a differentiated approach compared with traditional site networks or recruitment vendors.[4][5][9][12][15]
• High-quality, returning investor base supporting the Series A2 round. Backing from reputable investors such as Cathay Innovation, Obvious Ventures, Serena, and Fly Ventures in prior rounds, and the presence of returning investors in 2023, lends credibility and signals confidence in the business.[1][4][9][13][14][15]
• Well-articulated growth and product roadmap tied to the raise. Use-of-funds messaging around product innovation, international expansion, and hiring shows a concrete plan to deploy capital toward scaling and deepening the platform’s impact.[1][9][14]
• External validation of innovation and impact in inclusive clinical trials. Recognition by outlets such as Fast Company for improving representation and diversity in trials reinforces the company’s positioning and likely appeared as reputational evidence in or around the deck.[10]
• International footprint aligned with global sponsor needs. Presence in both Europe (Paris HQ) and the U.S. (Guilford, CT) supports a global marketplace narrative attractive to pharma sponsors operating multinational trials.[4][9][11]

What could have been stronger

• Limited publicly visible traction metrics in the 2023 fundraising narrative. External coverage emphasizes strong mission and marketplace concept but provides limited quantified traction at the time of the 2023 raise (e.g., numbers of active sponsors, sites, trials, or revenue), making it harder for investors to assess scale and growth purely from publicly visible information about the deck.[1][4][9][10][15]
• Inconsistent reporting of round size and labeling across sources. Although the raise is described as Series A or Series A2, public databases and press disagree on the exact amount ($20M vs. about $21.3M), which could introduce ambiguity in financial storytelling if not addressed clearly in the deck and investor discussions.[1][6][7][9][13]
• Sparse external detail on regulatory and integration strategy. Press and company materials stress inclusivity and access but provide fewer externally visible details on regulatory strategy, data compliance, and integration with sponsor workflows, which investors often scrutinize for clinical trial technology platforms.[1][4][5][9][10]
• Limited public detail on business model economics. Information available focuses on the marketplace positioning rather than clear unit economics or pricing for sponsors and sites, potentially leaving questions about long-term margins and business model resilience.[4][5][9][15]

How an investor would read this deck

What draws attention

• Ability to unlock recruitment at underused community sites and improve diversity of patient populations in trials, addressing a major industry pain point.[4][5][9][10][15]
• Strength of marketplace network effects between sponsors and thousands of community-based research sites, and how defensible this position can become over time.[4][5][9]
• Demonstrated traction with biopharmaceutical sponsors, including the number of trials and sites active on the platform at the time of the raise.[4][9][10]
• Regulatory, data privacy, and compliance framework supporting AI-driven matching and site engagement in highly regulated markets.[5][11][12]
• Use of funds from the 2023 round to drive product innovation, international expansion (especially U.S. growth), and key hires.[1][9][14]

Risks that stand out

• Clinical trial recruitment is a crowded space with multiple technology and service providers; Inato must maintain a distinct value proposition around inclusive community sites and AI matching to avoid commoditization risk.[4][5][9][15]
• Dependence on biopharmaceutical sponsors’ budgets and adoption cycles may expose the business to macro cycles in R&D spending and slow enterprise sales processes.[4][9][15]
• Operating in a highly regulated environment introduces ongoing compliance, data security, and liability risks, especially when leveraging AI and large datasets.[5][11][12]
• Execution risk around scaling internationally while maintaining quality of site engagement and support, particularly across heterogeneous healthcare systems and languages.[1][4][9][11]
• Potential confusion around round labeling and size (Series A vs. Series A2, $20M vs. ~$21.3M) underscores the need for clear investor communication and consistent reporting.[1][6][7][9][13]

Questions this deck invites

• What specific quantitative traction (e.g., number of trials, sponsors, active sites, and patient enrollments) had Inato achieved by the time of its 2023 Series A/Series A2 round, and how has that evolved since?[1][4][9]
• How does Inato’s marketplace pricing work for sponsors and sites, and what are current gross margins, contribution margins, and sales cycles with biopharma clients?[4][5][9]
• What regulatory, data privacy, and security frameworks does Inato follow, and how has the platform been validated or audited by major sponsors or regulators?[5][11][12]
• How sustainable are the company’s network effects and competitive moat compared with other clinical trial technology platforms or recruitment services?[4][5][9]
• What concrete milestones did Inato set for product innovation, international expansion, and hiring with the 2023 funds, and which of these have been achieved to date?[1][9][10][14]

What founders can take from the Inato deck

• A clear, mission-driven narrative around making clinical trials more inclusive and accessible to underrepresented communities can resonate strongly with both investors and media when backed by a specific marketplace model.[1][4][5][9][10][15]
• Positioning as a two-sided marketplace that uniquely connects sponsors to community-based sites creates a differentiated story in a crowded clinical trial technology space.[4][5][9][15]
• Leveraging existing relationships with prior investors (e.g., Cathay Innovation and Obvious Ventures) can anchor a follow-on Series A2 round and signal confidence in the company’s trajectory.[1][9][13][14][15]
• Articulating the use of funds around product innovation, international growth, and hiring helps investors understand how capital will translate directly into expanded impact and scale.[1][9][14]
• Public consistency in describing round type, size, and purpose matters; discrepancies between databases and press highlight the importance of maintaining a clear external capital narrative.[1][6][7][9][13]
• Explicitly tying AI capabilities to concrete marketplace outcomes (better matching of sites and protocols, more diverse patient enrollment) strengthens the credibility of an AI story in healthcare.[4][5][11][12]

Inato pitch deck: common questions

What does Inato do?

Inato is a Paris-based healthcare technology company that runs a global marketplace and AI-powered platform to match community-based research sites with appropriate clinical trials, helping sponsors run more inclusive, efficient studies.[4][5][11][12]

How much did Inato raise in its 2023 Series A round, and who invested?

In March 2023, Inato announced a $20M Series A2 funding round (often described as Series A) led by Cathay Innovation, with participation from Obvious Ventures, La Maison, and Top Harvest Capital.[1][9][13][14] Some databases list the round as approximately $21.3M, but the company and most press consistently cite $20M.[1][6][7][13]

What was the purpose of Inato’s 2023 Series A fundraise?

The 2023 Series A/Series A2 funding was raised to continue product innovation of Inato’s clinical trial platform, support international growth, and hire additional talent, enabling more inclusive trials and broader site participation.[1][9][14]

When was Inato founded and where is it based?

Inato was founded in 2016 in Paris, France, and has since expanded its presence to the United States (including offices in Guilford, Connecticut) while operating a global network of community trial sites.[11][15]

How much funding has Inato raised in total?

Public sources indicate Inato has raised at least $34M in total funding: a $14M Series A led by Obvious Ventures and Cathay Innovation in 2020, followed by a $20M Series A2 round in 2023, with some trackers reporting about $37.5M across four rounds.[4][9][13][15]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• Inato Raises $20 Million in New Funding to Make Clinical Trials ...
• Inato - Company Profile - Tracxn
• Inato: Funding, Team & Investors | Startup Intros
• Inato - PharmaFeatures
• Inato | One platform to run faster, more inclusive trials, together
• Inato 2025 Company Profile: Valuation, Funding & Investors | PitchBook
• Total Raised
• Inato — Company Profile

Inato pitch deck slides

What each slide of the Inato pitch deck says

Slide 2

The $50B clinical trial industry is broken Out-of-pocket cost per approved new drug W Pre-cLINICAL I CLINICALTRIALS $1.4b 1980 1990 2000 2010 2020 Source: Di Masi et al. (1991, 2003, 2016) inato | 2

Slide 3

Why? Pharma sponsors compete! for a small subset of patients 40% = of trials expenditures come from patient recruitment o, <5% ,@/@\ of patients participate in trials (while 70%+ are willing to) ical trials

Slide 5

We are building the largest research network in the world - without owning a single site ' Sponsor Trials Community Sites Patients k i (1,000s) (10,000s) (100,000s) i " Expand access to patients Access thousands of trials Access the right trial at the ' b through community to grow their research right time through their . sites practice trusted doctor

Slide 7

Our platform matches community sites to the right trials at scale Matching = Enrollment Belter recommendations lead to Sponsors posting more trial opportunities and Sites getting more trial recommendations &8 ‘Sponsors posts Trial opportunity on platform Sites get recommended relevant trials Sites apply to tial by planning their enroliment Inato leverages enoliment data Inato review plans, recommends the best ones with an toimprove recommendation & enrollment IVC" guaranteeing the enrollment performance performance Sponsors selects recommended sites based on their st:\é‘:“:im‘:f; e""’"‘g IVCs / planning and move to activation H i IVC is “Inato Verified Commitment - number of patients a site…

Slide 11

Beyond 2024, unlocking access to trials to 100,000s of patients per year oy inato prliec g 3 e v | ponsor | Patients ] 3 Trials /. h Matching Site services The more we grow, the better we become at matching By supporting sites beyond matching, we help them grow trials with the right community sites. their research practice & reach more patients. As we expand to hundreds of trials on the platform The more active we become in identifying eligible annually, our matching algorithm will advance its precision, positioning Inato as sponsors’ go-to when it comes to selecting sites across their portfolio, patients & matching them to the right trials, the more value we can capture per patient. $3B TA…

Slide 13

We are uniquely positioned to become the largest research network globally inato » Integrated Research Patient Decentralized Clinical Unlock access to trials Large nonprofit nitiatives from Train & supportnaive sitesto Match patients to trials Enables remote/virtual through experienced consortiums of sites (TOP) or build research capabiliies. through EHR integrations, patient visits communty sites. sponsors (SIP). site workflow or patient Model Strong integrationsbutlow portals Lack relationships with Scalable, global model Did notreach PMF forboth scalabilty, margins & high sites who will continue to with strong network sides of the platform chum Notinvolved in site play a key role for key…

Slide 14

We have achieved strong Product-Market fit with Sites O, “The platform's capability for recording sites g 1 /o areas of research interest for potential study matches is a tremendous value to sites. [..] While ['fl} of sites claim they would be getting study awards is always a site priority, it disappointed if they could no does no one any service when the match ) between study needs & site capability is poor.” longer work with Inato SITE MANAGER - BOSTON PAINCARE CENTER Our value resonates with all sites, Sponsors select them across all experience categories i inato | 14 Source! Q3-22 Site sati

Slide text above is read directly from the Inato deck PDF embedded on this page.

Guides that feature Inato’s slides

• How to Show Repeat Purchase Rate on Your Pitch Deck
• Key Insight Slide
• Value Chain Slide

Related fundraising guides (24)

• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Heura Pitch Deck Teardown: Dominating the Mediterranean Plant-Based Market
• Fintor Pitch Deck Teardown: A $6.2M Seed Round Built on Fractional Real Estate Liquidity
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Bramble Energy Pitch Deck Teardown: Leveraging PCB Supply Chains for Hydrogen Fuel Cells
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Thematic Pitch Deck Teardown: Leveraging Creator Networks for Scalable Music Promotion
• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery
• Hint Health Pitch Deck Teardown: Scaling Direct Primary Care Infrastructure
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI
• Code First Girls Pitch Deck Teardown: A Masterclass in B2B Social Impact Scaling
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• AgBiome Pitch Deck Teardown: A $116M Series D Masterclass in Platform Validation
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Viso Pitch Deck Teardown: A 42-Slide Masterclass in Computer Vision Infrastructure
• Hopscotch Pitch Deck Teardown: A $8M Seed Round for Pediatric Behavioral Health Infrastructure
• Groundcover Pitch Deck Teardown: Leveraging eBPF to Disrupt Cloud Observability Costs

Decks from the same year (1)

• 2023 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $10M to $50M

Browse companies alphabetically (1)

• Pitch decks from companies starting with I

More pitch deck teardowns (16)

• iMocha Pitch Deck Teardown: A Case Study in Redacted Metrics and Enterprise Traction
• IMPACT Silver Pitch Deck Teardown: Leveraging a Tesla Partnership for Modern Mining
• Impossible Foods Pitch Deck Teardown: A Masterclass in Brand-First Storytelling
• Impossible Kicks Pitch Deck Teardown: Scaling High-Volume Physical Retail for Sneaker Resale
• Improvado Pitch Deck Breakdown: A Masterclass in Product-Led Technical Simplicity
• Atooma Pitch Deck Teardown: A Context-Aware Middleware Play for the Early IoT Era
• Makoo Pitch Deck Teardown: Turning Voice Waves into 3D-Printed Jewelry
• Teowaki Pitch Deck Teardown: A Developer-Centric Social Network for Technical Knowledge Sharing
• Incentify Pitch Deck Breakdown: A Masterclass in Quantifying the Unclaimed Asset Class
• inCitu Pitch Deck Teardown: Using Augmented Reality to Solve the NIMBY Crisis
• Included Health Pitch Deck Breakdown: A Case Study in B2B2C Healthcare Advocacy
• Include Pitch Deck Teardown: Scaling Smart City Infrastructure Through Global Distribution
• Incluzion Pitch Deck Teardown: A Niche Marketplace Play for Diverse Agile Talent
• Incredible Health Pitch Deck Breakdown: A Masterclass in Marketplace Speed and Social Proof
• INCYMO AI Pitch Deck Breakdown: Targeting the $71.5B Mobile Game Ad Creative Market
• Incymo AI Pitch Deck Teardown: Targeting the Mobile Gaming Ad Creative Bottleneck

Recently published pitch deck teardowns (12)

• Postmates Pitch Deck Breakdown: A 2011 Masterclass in Logistics Disruption
• Alyce Deck Breakdown: Targeting the $120B Waste in B2B Physical Outreach
• 900.care Pitch Deck Teardown: Scaling 'Shower Gel as a Service' to a $22.7M Series A
• Anam Pitch Deck Teardown: A Technical Bet on Real-Time AI Human Interfaces
• Anvil Pitch Deck Teardown: A Masterclass in High-Level Narrative and Product Abstraction
• Amplify Pitch Deck Teardown: A $20M Series B Masterclass in Market Re-Education
• Dstlry Pitch Deck Teardown: A Creator-First Play for the Digital Collectibles Market
• DryMerge Pitch Deck Teardown: A Masterclass in Minimalist Seed Stage Storytelling
• EarnOS Pitch Deck Teardown: Leveraging zkTLS to Monetize Verifiable Human Attention
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Genie AI Pitch Deck Teardown: A Masterclass in Technical Credibility and Growth Velocity
• Kluster Pitch Deck Teardown: A Masterclass in Product-Led Series A Storytelling

Fundraising library · Pitch deck examples · Investor directory · Founder database